Aims: We describe outcomes in pts with SEA, with and without comorbid NP, treated with benralizumab in the XALOC-1 study programme.

Methods: This integrated analysis of retrospective data from Canada, Italy, Portugal, Spain, and the UK assessed annualised exacerbation rates (AER), maintenance OCS (mOCS) use and pt-reported outcomes (PROs; 6-item Asthma Control Questionnaire [ACQ-6] or Asthma Control Test [ACT]).

Results: Overall, pts (n=1002) had a mean (SD) age of 55.4 (13.7) years and 58.6% were female. In the 31.5% (n=316) with comorbid NP (based on medical records available at treatment initiation), mean (SD) age was 54.1 (12.5) years and 50.3% were female. By Week 48, pts with and without comorbid NP experienced similar reductions in AER and pts with mOCS use, and improvements in PRO scores (Figure). In pts using mOCS at baseline, mean dosage decreased 58.2% by Week 48 in pts with comorbid NP (n=97) and 46.8% in those without (n=179). 73.0% (73/100) of pts with comorbid NP and 65.2% (133/204) of those without, experienced improvements matching or exceeding minimal clinically important differences in ACQ-6 (?0.5) or ACT (3) scores.

Conclusions: Patients with SEA treated with benralizumab experienced substantial improvements in asthma outcomes, regardless of the presence or absence of comorbid NP.